CD95 is a dual-function receptor that exerts pro-or antiapoptotic effects depending on the cellular context, the state of activation, the signal threshold and the mode of ligation. In this study, we report that CD95 engagement modulates TCR/CD3-driven signaling pathways in resting T lymphocytes in a dose-dependent manner. While high doses of immobilized CD95 agonists silence T cells, lower concentrations augment activation and proliferation. We analyzed the co-stimulatory capacity of CD95 in detail in resting human CD4 þ T cells, and demonstrate that low-dose ligand-induced co-internalization of CD95 and TCR/CD3 complexes enables non-apoptotic caspase activation, the prolonged activation of MAP kinases, the upregulation of antiapoptotic proteins associated with apoptosis resistance, and the activation of transcription factors and cell-cycle regulators for the induction of proliferation and cytokine production. We propose that the levels of CD95L on antigen-presenting cells (APCs), neighboring T cells or epithelial cells regulate inhibitory or co-stimulatory CD95 signaling, which in turn is crucial for fine-tuning of primary T-cell activation. Cell Death and Differentiation (2011) 18, 619-631; doi:10.1038/cdd.2010.134; published online 5 November 2010
For activation of resting T cells, two signals are required. The first signal emerges from an engagement of the T cell receptor (TCR)/CD3 complex, whereas the second signal is generated through the ligation of co-stimulatory receptors (i.e. CD28). Recently, 'tumor necrosis factor (TNF) receptor-associated factor' (TRAF) binding receptors were identified as a second class of co-stimulatory receptors. 1 As an example, Alderson et al. 2, 3 provided first evidence for the role of CD95 (Fas, APO-1), the prototypic death receptor of the immune system, in the activation of human T cells. It was subsequently reported that CD3-crosslinking alone or CD3/CD95 costimulation induces the processing of caspase-8 and/or caspase-3 as a prerequisite for full T-cell proliferation. [4] [5] [6] CD95 co-ligation also influences several other routes of intracellular signal transduction. Kataoka et al. 7 reported the activation of NF-kB-and mitogen-activated protein kinase (MAPK)-related pathways following an interaction of CD95-recruited 'cellular FLICE-inhibitory protein' (cFLIP) with downstream signaling molecules. Apparently, this process required the cleavage of cFLIP into a p43 fragment. More recently, however, it was argued that p22-FLIP (but not p43) can activate NF-kB by directly interacting with the IKK complex. 8 So far, three cFLIP isoforms (cFLIP L , cFLIP S and cFLIP R ) were identified, with cFLIP S/R mediating a block in apoptosis by inhibiting procaspase-8 at the death-inducing signaling complex (DISC). The role of cFLIP L regarding an inhibition at the DISC is still a matter of debate. 8, 9 Further downstream, antiapoptotic proteins including Bcl-2/Bcl-X L and 'X-linked inhibitor-of-apoptosis protein' (XIAP) may prevent apoptosis. 9, 10 A decreased expression of antiapoptotic checkpoint proteins in CD95-sensitive cells could therefore shift NF-kB-associated proliferative signaling pathways to caspase-associated death signaling in the course of cellular activation. 11 We now report that CD95 engagement modulates the activation of primary human CD4 þ T cells in a dosedependent manner. Whereas high concentrations of CD95 agonists result in the block of activation, low concentrations augment TCR-induced proliferation. As this differential signaling capacity was seen for different ligands, it points to a novel mechanism to regulate T-cell activation in a contextspecific manner. In addition to the inhibitory effect (recently described by Strauss et al. 12 ) we provide a detailed analysis of signaling events associated with the positive co-stimulatory function of CD95. We demonstrate that CD95 ligation with low doses of agonists promotes TCR-triggered MAPK phosphorylation, non-apoptotic caspase activation, and the upregulation of activation markers and antiapoptotic checkpoint proteins. As a consequence, enhanced cell-cycle progression, proliferation and cytokine production are associated with a generalized partial apoptosis resistance.
Results

Modulation of primary T-cell activation by CD95
engagement. To analyze the effects of CD95 ligation on the TCR/CD3/CD28-induced activation of freshly isolated peripheral blood mononuclear cells (PBMCs), we initially immobilized anti-CD3 monoclonal antibody (mAb) þ /À anti-CD28 mAb in the presence or absence of CD95LFc, huIgGFc or agonistic anti-CD95 mAb (7C11). As shown in Figure 1a , TCR-induced proliferation was significantly reduced in the presence of CD95LFc, but augmented in the presence of anti-CD95 mAb. Immobilization was mandatory to modulate T-cell activation, as soluble factors had no effect (not shown). Moreover, stimulation by co-immobilized anti-CD28 mAb did not alter the outcome. When we analyzed purified CD4
þ T cells (Figure 1b -d), we observed an almost complete block of TCR-induced cluster or blast formation and proliferation in the presence of CD95LFc, but a massive activation using anti-CD95 mAb (anti-APO-1). The CFSE profiles indicated that upon CD3/CD28 stimulation, anti-CD95 co-ligation induced cell-cycle progression in the entire population, whereas in the absence of anti-CD95 significantly fewer cells divided. Importantly, neither immobilized CD95LFc nor immobilized anti-CD95 mAb induced significant cell death of resting T cells during the observation period (Figure 1e ). Dose-dependent effects of CD95 co-ligation. As the effects of immobilized CD95 agonists were seen at coating concentrations of 20-40 mg/ml for fusion proteins and 2-5 mg/ml for mAb, we wondered whether the co-stimulatory function would depend on the dose of agonists. To test this, CD4 þ T cells were stimulated with anti-CD3/CD28 in the absence or presence of CD95 agonists that were co-immobilized at various concentrations. T-cell activation was monitored by the expression of CD25 and CD69 at d1 (Figure 2 ). Although CD95LFc, CD95L-ST-Fc, LZ-CD95L and anti-APO-1 at high concentrations inhibited the expression of both activation markers, lower amounts of agonists led to an increased number of CD25/CD69 double-positive cells. This dosedependency was seen for all ligands tested, although the degree of inhibition and stimulation varied to some extent between individual donors. Of note, the apoptosis-inducing capacity of all CD95 reagents was confirmed using pre-activated phytohemagglutinin (PHA) blasts and soluble agonists (Supplementary Figure S1 ). In addition, as exemplified for LZ-CD95L, at the tested concentrations, soluble CD95 ligands alone only mildly affect the viability of the freshly isolated CD4 þ T-cell population.
CD95 co-stimulation augments TCR-induced cytokine production. Co-immobilization of anti-CD95 augmented the production of IL-2, interferon gamma (IFNg) and TNFa, but hardly influenced the level of IL-4 ( Figure 3 ). As expected, IL-2 production depended on CD3 stimulation and was further enhanced by CD28 co-stimulation ( Figure 3a ). CD95 ligation alone had no effect. In the presence of anti-CD95, CD3-stimulated T cells initially produced less IL-2 compared to CD3/CD28-triggered cells. However, higher levels of IL-2 were detected at d2/3 by ELISA, and also by intracellular FACS staining (Supplementary Figure S2A) . To document the strong co-stimulatory capacity of CD95 irrespective of the used agonist, the data were verified by costimulation with low amounts of CD95LFc (Supplementary Figure S2B ). In line with the growth inhibition at high doses of CD95LFc, also the IL-2 production was reduced compared to CD3-stimulated cells (Supplementary Figure S2B) . The presence of exogenous IL-2 hardly affected the activationinduced CD25 expression (Figure 3b and Supplementary Figure S2C ), arguing that the CD3/28/95-induced IL-2 production sufficed for optimal initiation of T-cell activation. Also, the CD3/CD28-induced production of IFNg and TNFa was significantly enhanced in the presence of low doses of anti-CD95 ( Figure 3c ). As shown in Supplementary Figure  S3A , similar results were obtained using low versus high doses of other agonists, for example, CD95L-ST-Fc. Notably, IL-4 production was almost unchanged, indicating a more pronounced effect of CD95 ligation on T helper 1 (Th1)-type cells. Consistent with this, T-bet, a known regulator of Th1 differentiation, was upregulated and phosphorylation of STAT-1 and STAT-4 was enhanced only in the presence of low-dose anti-CD95 (Figure 3d ) or CD95L-ST-Fc (Supplementary Figure S3B) .
CD95 affects the expression of activation markers and TCR-associated signaling pathways. As shown in Figure 4 and Supplementary Figure Figures S6 and S7) .
When comparing CD3-stimulated and CD3/CD95-stimulated cells regarding the kinetics of extracellular signalregulated protein kinase (ERK) phosphorylation, we did not observe major differences in short-term cultures up to 30 min. However, whereas ERK phosphorylation of TCR/CD3-triggered cells was transient and declined thereafter, in the presence of anti-CD95, we detected a prolonged phosphorylation for up to 48 h (Figure 4c ). This enhanced ERK activation was also seen for low-dose CD95L-ST-Fc (Supplementary Figure S8) . In this scenario, treatment with the ERK1/2 inhibitor PD 98059 (PD) significantly blocked cell activation and proliferation (Figure 4e, Supplementary Figure S9 ) in the absence of cell death (Supplementary Figure S9A) , indicating that ERK signal transduction is crucial for the antiapoptotic CD95-mediated co-stimulatory capacity. In contrast, and in line with the report by Strauss et al., 12 T cells co-incubated with high concentrations of CD95 agonists showed a Figure S8A) . Notably, T-cell activation induced by phorbolester (PMA) and calcium ionophore (ionomycin) was not affected by CD95 ligation, neither at high nor at low concentrations ( Figure 4f ).
CD95 crosslinking enhances TCR internalization. TCR/ CD3 complex internalization is associated with optimal activation through the formation of intracellular signaling platforms. 13 As shown in Figure 5a and b and Supplementary Figure S10A þ T cells were incubated in X-VIVO medium with immobilized anti-CD3 mAb or PHA for the indicated time periods in the presence or absence of plate-bound anti-CD95 mAb anti-APO-1 (5 mg/ml) (a-c, e and f) or CD95L-ST-Fc (2,5 mg/ml) (e) as well as high doses of CD95L-ST-Fc (d) or CD95LFc (f) (both 20 mg/ml). The expression of CD69 (a and b) and other activation markers (b) was determined between 1-8 h (a), and at d2 (b) of incubation by flow cytometry using FITC/PE-labeled anti-CD69, anti-OX40, anti-CTLA-4, anti-CD25, anti-IL-2Rb and anti-CD95L mAb, respectively. Expression levels are given as MFI and are representative of three independent experiments with different donors. (c-d) After incubation at 371C for the indicated time points, T cells were lysed and aliquots of 20 mg of the whole-cell lysate were analyzed by western blot using antibodies against phospho-ERK and ERK as a loading control. (e) Cells were treated in the presence or absence of the ERK1/2 inhibitor PD 98059 (50 mM) or DMSO for 3 days before MTS assay. The experiment was performed in triplicates. Error bars represent S.Ds. from the mean. Statistical differences were calculated by student's t-test: **Po0.01. (f) CFSE-labeled CD4 þ T cells were incubated in the presence of PMA, ionomycin or PMA/ionomycin with or without 20 mg/ml CD95LFc or 2 mg/ml anti-CD95 mAb (7C11), respectively. CFSE profiles were measured at d3 low-dose CD95 co-stimulation within the first 8 h of incubation, and even more pronounced after 48 h. At the same time, CD69 expression was upregulated, indicating that CD95 crosslinking selectively down-modulated TCR surface availability (Supplementary Figure S10B) .
CD95 triggering is associated with receptor internalization. Also for members of the TNF receptor (TNFR) superfamily, receptor internalization has been associated with the generation of intracellular signaling platforms. In case of TNFR1 or CD95, internalized receptosomes contain several pro-apoptotic molecules.
14 To test whether CD95 internalization might also be associated with nonapoptotic CD95 signaling, we analyzed CD95 surface expression following stimulation (Figure 5c -e, Supplementary Figure S10C ). In the absence of CD3 stimulation, Figure S10C) . Importantly, CD69 expression followed the patterns described before (Figure 5d ). Using a set of inhibitors for metalloproteases (GM6001, TAPI), clathrindependent endocytosis (monodansyl cadaverine), microtubule (colchicine) and actin polymerization (cytochalasin D (CytD), latrunculin A (LatA)), we observed a dose-dependent reduction of CD95 internalization only in the presence of CytD and LatA (Figure 5e ), indicating that an actin-dependent mechanism might control this process. Because of the inhibition of actin polymerization, we observed a complete block of CD3/CD28-driven T-cell proliferation (Supplementary Figure S10D) without detectable cell death (Supplementary Figure S10E) . Thus, we suggest that abolished CD95 internalization results in T-cell silencing.
CD95 co-stimulation induces caspase activity and expression of antiapoptotic proteins. To address whether CD95-triggered caspase activity would also contribute to TCR-induced activation, we analyzed caspase processing and activity ( Figure 6 ). In line with earlier reports, 4-6,10,15 increased caspase-3/-8 activities were detected in lysates of TCR-stimulated cells, and caspase activity was further enhanced by co-stimulation with anti-CD28 or low amounts of anti-CD95 or CD95LFc. The importance of active caspases in this scenario was illustrated by the addition of the pan-caspase inhibitor ZVAD-fmk. Caspase inhibition resulted in a drastic reduction of CD25 expression and inhibited proliferation without provoking apoptosis (Supplementary Figure S11) . Interestingly, caspase activation during positive CD95 co-stimulation was even higher than the activity seen in apoptotic Jurkat T cells (Figure 6a , lower panels). In contrast, CD95 ligation using CD95LFc at high concentrations completely blocked caspase activation in resting cells. Positive CD95 co-stimulation significantly increased the level of cleaved caspase-3 (p20) (Figure 6b and c) . As shown in Figure 6c , the partial caspase-3 processing was associated with an increase of active caspase-8 (p41/p43). Although the p20 product of caspase-3 and the p41/p43 intermediates of caspase-8 seem to be capable of cleaving the fluorogenic caspase-3/-8 substrates, we did not observe a significant cleavage of apoptosis-associated substrates (i.e., PARP, phospholipase Cg (PLCg). Therefore, pro-and antiapoptotic caspase signaling might depend on a differential processing of caspase-3. Taken together, we show that activation of primary T cells correlates with caspase processing and in vitro caspase activity.
Apoptotic death receptor signaling can be intrinsically regulated at several levels by cFLIP R/S , p43-and p22-FLIP as well as antiapoptotic Bcl-2 family members like Bcl-X L . As illustrated in Figure 6d , TCR stimulation resulted in a mild upregulation of Bcl-X L , cFLIP R/S and p22-FLIP. Low-dose anti-APO-1 co-ligation strongly enhanced the expression of all antiapoptotic proteins that were tested ( Figure 6d ). As NF-kB activation is linked to cFLIP signaling, we also observed enhanced phosphorylation of IkB. Upregulation of cFLIP R/S , Bcl-X L and activation of NF-kB are associated with cell survival. Therefore, we asked whether CD95 co-stimulated cells also display apoptosis resistance to other stimuli. Upon TCR stimulation and more pronounced upon costimulation by CD95, we indeed observed a partial apoptosis resistance when the pretreated cells were collected at d2, and either g-irradiated or exposed to toxic mistletoe lectin 16 ( Figure 6e ).
Accelerated cell-cycle progression of TCR-stimulated cells by low-dose CD95 co-ligation. We next addressed whether CD95 co-stimulation influences cell-cycle progression during primary T-cell activation (Figure 7) . Although anti-CD95 alone did not influence the cell-cycle profile, CD3 and CD3/28 stimulation resulted in the expected mild increase of cells within the S-or G2/M-phase. Costimulation by anti-CD95, however, resulted in a massive induction of proliferation with 45% of the cells entering S-and G2/M-phase in the absence, and 55% in the presence of anti-CD28. In this study, the co-stimulatory capacity of anti-CD95 was even stronger than the anti-CD28-induced costimulation. The differential effect of low versus high dose of agonists on cell-cycle progression was confirmed using the CD95L-ST-Fc fusion protein (Supplementary Figure  S12) . Similarly, when the T cells were analyzed for the production of ATP, low amounts of CD95L-ST-Fc elevated ATP levels, while high ligand concentrations reduced the anti-CD3/CD28-induced ATP production (Supplementary Figure S12D) . At the level of protein expression, we analyzed the appearance of cell-cycle-regulating proteins at d2. Compared to the unchanged level of ERK, all tested cell-cycle-regulating proteins, including CDKs, cyclins and proliferating cell nuclear antigen (PCNA) (see also Figure 6 Low-dose CD95 co-engagement induces caspase activation, expression of antiapoptotic proteins and promotes apoptosis resistance. Caspase-3/-8 activity (a) and processing (b and c) as well as cleavage of caspase substrates (c) were determined after incubation of primary human TCR-stimulated cells in the presence or absence of the indicated CD95 agonists at different concentrations. (a) Cleavage of the caspase-3/-8 specific substrates Ac-DEVD-AMC/Ac-IETD-AMC, followed by the release of the fluorogenic AMC, was used to detect activity of caspase-3/-8 in lysates from T cells incubated for 3 days with or without anti-CD3 þ /À anti-CD28 mAb in the presence or absence of anti-CD95 mAb (anti-APO-1, 5 mg/ml (C3)) or CD95LFc (2.5 (C2) and 40 mg/ml (C1)). An AMC fluorescence reference standard was used to calibrate the AMCbased caspase substrates in order to quantify caspase activities (a, lower panel). In this study, we included the caspase activity of Jurkat T cells incubated with 5 mg/ml of soluble CD95LFc for 2 h to induce apoptosis. as a dual-function signaling receptor that can give rise to pro-and antiapoptotic signals depending on the cellular microenvironment. 2 We now show that CD95 also functions as a dual-function modulator during TCR/CD3-initiated activation of primary human T cells. The outcome of CD95 ligation on naïve T cells largely depends on the 'dose of agonist', resulting in opposite effects from a complete block of activation at high doses to a prominent co-stimulatory activation at lower concentrations. In our report, we focus on the growth-promoting function of CD95 on human CD4 þ T cells. In essence, CD95 co-stimulation is only seen in the context of TCR/CD3 stimulation, does not require an additional signal (e.g. through CD28), and strictly depends on immobilization of the CD95 agonists.
Antiapoptotic or co-stimulatory consequences of CD95 engagement have been described for different cell types during liver regeneration, neurite outgrowth, development and functional recovery of the central nervous system, and proliferation of growth factor deprived fibroblasts. 17 Also, for T lymphocytes, earlier work pointed to a potential modulation of T-cell activation by CD95. 3, 4 However, the molecular mechanisms of this co-stimulatory function have never been elucidated. Recently, Strauss et al. 12, 18 reported that CD95 co-stimulation blocks the activation of naïve T cells by inhibiting TCR signaling. This is in line with our observations using high concentrations of CD95 agonists, and thus reflects the inhibitory branch of CD95 signaling. As the effective concentrations of antigen-presenting cell (APC)-expressed or plate-bound agonists in the two studies are difficult to correlate, we suggest a narrow threshold window for switching the response from full activation to silencing (supported by our titration experiments). Notably, as for most analyses employing primary human T cells, we also observed donor-related variations of the fraction of co-stimulated cells and the signal amplitude.
A dose-dependency of CD95 ligation was noted earlier for CD95-sensitive SKW6.4 cells. 19 Also in this study, CD95 stimulation below a certain threshold level triggered survival, whereas strong CD95 stimulation initiated cell death. However, in contrast to SKW6.4 cells or activated T cells, freshly isolated T cells display apoptosis resistance even to high concentrations of CD95 agonists. As a consequence, high concentrations rather interfere with TCR signal initiation, and ultimately result in T-cell silencing without inducing cell death. In contrast, low concentrations promote a sustained amplification of various TCR-induced activation parameters, including receptor internalization, ERK phosphorylation, expression of antiapoptotic proteins or activation markers, and cell-cycle progression.
For both TCR and CD95 signal initiation, receptor endocytosis has been implicated in the formation of respective signaling platforms important for cellular activation. 14, 20 Although the exact mechanisms of TCR internalization are still poorly understood, it in part depends on clathrin-mediated endocytosis. 13 Our observations suggest that low-dose CD95 engagement enhances the TCR translocation. However, it is still unclear how this mechanistically relates to CD95 endocytosis and to the generation of a common growthpromoting signaling platform. Notably, an ezrin-dependent route of internalization was recently described to counteract cell death induction and promote antiapoptotic functions of CD95. 21 Interestingly in this context, in contrast to CD95-mediated cell death induction, CD95 localization in raft nanodomains has very recently been shown to be dispensable for non-apoptotic CD95 internalization and signaling. 22 Our own analyses suggest an accelerated actin-dependent CD95/TCR co-internalization as a mechanism to establish receptor interference and signaling crosstalk.
MAPKs such as ERK are regarded as key switches of cellular activation and proliferation. In the context of low-dose co-stimulatory CD95 signaling, we observed a prolonged ERK phosphorylation. ERK activation in response to non-apoptotic CD95 triggering was reported before for glioma cells 23 and fibroblasts. 11 Moreover, in primary murine T cells, stimulation with anti-CD3/CD95 caused an ERK-dependent induction of AP-1-dependent luciferase activity. 24 Notably, TCR silencing in the presence of high amounts of CD95L is associated with a complete inhibition of CD3/CD28-mediated ERK activation. 12 Circumventing TCR ligation with phorbolester and calcium ionophore indicates that CD95 ligation affects TCR signaling upstream or independent of calcium mobilization and PKC activation.
Although caspase activation is a hallmark of apoptosis, 9 it has also been associated with lymphocyte activation. 4, 15, 25 We indeed detected elevated caspase-3/-8 activities in lysates of proliferating T cells. Co-ligation of CD28 or CD95 led to a comparable increase in caspase activity in this in vitro assay, again indicating that low-dose CD95 co-stimulation might in fact replace CD28 signaling. In agreement with Strauss et al.,
12 CD95 agonists at high concentrations blocked caspase activity in the same assay. As pro-apoptotic caspase substrates were never cleaved, we suggest that caspase activation is required for proliferation, but that non-or pro-apoptotic caspase activation is qualitatively different. 15 In the case of the effector caspase-3, we only observed the formation of the p20 cleavage fragment, but not of p17/p19, which is found in apoptotic cells. In view of our recent observation that XIAP can interact with caspase-3 and thereby blocks full caspase activation, 10 we suggest that in naïve T cells, CD95 initiates an incomplete cleavage of caspase-3, thereby presumably hindering the cleavage of pro-apoptotic substrates. Thus, mitogenic caspase-3 activation might affect a different subset of substrates, which in turn are crucial for mounting a proliferative response. Nonetheless, it is still a matter of debate whether CD95 directly activates caspases via its adapter molecule FADD or whether CD95 only supports the TCR-mediated activation of caspases mediated by a signaling complex formed by Bcl-10, CARMA1 and MALT1. 26 Given that cFLIP R/S and the Bcl-2 family member Bcl-X L are known for their capacity to protect from apoptotic cell death, 9 we observed a more generalized apoptosis resistance after TCR activation and co-stimulation by CD95. The crucial role of antiapoptotic proteins was underscored by the fact that ABT737, an inhibitor of antiapoptotic Bcl-2 family members, abolished CD3/CD95-mediated apoptosis resistance (not shown). In this context, it has also been noted that antiapoptotic FLIP isoforms do not just block the initiation of the extrinsic apoptotic pathway, but also result in increased survival after TCR engagement and protect from spontaneous apoptosis. 27 It was proposed that the expression of CD95L on APC would be responsible for antigen-specific deletion of primed peripheral T cells, eventually leading to T-cell tolerance or immunosuppression. 28, 29 More recent data, however, provide evidence for alternate activities of APC-associated CD95L on naïve T cells, including the complete block of T-cell activation in the absence of apoptosis and proliferation. 12, 28 This is in line with an earlier report by Chen et al., 30 who observed an inhibition of T-cell proliferation by 'CD95L-painted' K562/B7-1 cells that was only partially caused by apoptosis induction. However, in this study, a positive co-stimulatory effect of CD95L had not been noted.
On B cells 31 and APC, 32 CD95L might be upregulated in the course of an immune response by yet unknown mechanisms accompanying antigen processing and presentation. 32 It was suggested that macrophages upregulate CD95L during HIV infection 33 and thereby contribute to the apoptotic depletion of uninfected CD4 þ T cells. According to the report by Strauss et al., 12 another mechanism of reducing T-cell numbers might be the proliferation block of resting cells. Apparently, the outcome of CD95 ligation very much depends on the state of activation of the respective T-cell population. Also, CD95L-expressing dendritic cells (DCs) trigger apoptosis of preactivated cells, but induce resistance or even proliferation of naïve T cells. 28, 34 Under pathophysiological conditions, increased levels of CD95L might prevent initial T-cell expansion. Respective scenarios have been reported for HIV, 12 CMV 35 and others. In fact, Raftery et al. 35 observed that CMV-infected DCs not only down-modulate MHC molecules, but also upregulate CD95L, thereby inducing cell death of activated T cells and non-deletional suppression of the surviving T cells.
In conclusion, we suggest that, under physiological conditions, low-level CD95L on APC positively co-stimulates naïve T cells, allowing a first phase of expansion. During the immune response, CD95L is upregulated on APC and results in immune response termination by inducing apoptosis in pre-activated cells, and preventing the activation of additional effector cells. Under pathophysiological conditions, the threshold levels might be shifted to higher expression of CD95L, as a mechanism of immune evasion of certain pathogens.
Materials and Methods
Reagents and antibodies. TCR stimulation was performed with immobilized anti-CD3 mAb (OKT3, 2 mg/ml, IgG2a, Cilag, Sulzbach, Germany) and anti-CD28 mAb (CD28.2, 5 mg/ml, IgG1, BD Biosciences, San Diego, CA, USA). 96-well flatbottom tissue culture (TC) plates were coated for 3 h at 371C with 50 ml per well and 24-well TC plates with 250 ml of antibodies/fusion protein at the indicated concentrations in PBS. In some experiments, cells were stimulated with 10 ng/ml phorbolester PMA (Sigma, Munich, Germany) and 500 ng/ml ionomycin (Calbiochem, Darmstadt, Germany), or with PHA (PHA, 0.5 mg/ml, Remel, Dartford, UK). The anti-CD95 mAb 7C11 (IgM) was given to us by Michael J Robertson (Indianapolis, IN, USA) . In most experiments, however, we used the agonistic anti-CD95 mAb anti-APO-1 (IgG3) generated in PH Krammer's laboratory. 36 Human IgGFc was purchased from Bethyl Laboratories (Montgomery, TX, USA). Standard culture medium was X-VIVO (Lonza, Wuppertal, Germany). For some experiments, RPMI 1640 with glutamine, HEPES and antibiotics was used with 10% of pooled human AB serum (DRK, Baden-Baden, Germany) or 10% FBS (Biochrom, Berlin, Germany). Human recombinant interleukin-2 (rIL-2) (EuroCetus, Frankfurt, Germany), Protein A (Zymed Laboratories, South San Francisco, CA, USA), mistletoe lectin (Sigma), PD 98059 (Calbiochem), ZVAD(OMe)-fmk (Bachem, Weil am Rhein, Germany), LatA (Sigma) and cytochalasin D (Calbiochem) were added in some experiments as indicated.
Cells. PBMCs were isolated from buffy-coat preparations of healthy donors. CD4 þ T cells were MACS-purified using negative selection kits from Miltenyi Biotec (Bergisch-Gladbach, Germany) or Dynal (Invitrogen, Karlsruhe, Germany). In some experiments the CD4 þ T cells were further separated into CD45RA þ and CD45RO þ memory T cells using a depletion kit from Miltenyi Biotec. The purity of individual populations was examined by flow cytometry and reached routinely 95-99% of the desired phenotype. In some experiments, PHA-expanded T-cell blasts or Jurkat T cells (Je6.1) were used.
Flow cytometry. Purified T cells were incubated in untreated wells or in wells coated with anti-CD3 and anti-CD28 mAb in the presence or absence of co-stimulatory reagents as indicated. The cells were harvested and stained with fluorochrome-conjugated antibodies and analyzed using a FACS Calibur flow cytometer with Cellquest analysis software from Becton Dickinson. Changes in activation-dependent expression of surface molecules were tested with antibodies against CD95L (IgG1, Invitrogen), TCRa/b (MHAB01-4, IgG1, Caltag Laboratories, Hamburg, Germany), or CD25 (IL-2Ra, IgG1), CD69 (IgG1), CD122 (IL-2Rb, IgG1), CD134 (OX-40, IgG1) and CD152 (CTLA-4, IgG2a) from BD Biosciences. For the identification of CD95 internalization, cells were stained with anti-APO-1 (1 mg per 10 6 cells), followed by incubation with PE-labeled goat-anti-mouse secondary antibodies (1 : 60, Invitrogen). Cell viability was assessed by dye exclusion using propidium iodide (PI) (PI, Serva, Heidelberg, Germany) at 2.5 mg/ml in PBS. For intracellular FACS analyses, cells were fixed and permeabilized with Cytofix/ Cytoperm (BD Biosciences). Cells were resuspended in Perm/Wash and incubated for 30 min at 41C with fluorochrome-conjugated antibodies against IFNg, TNFa or IL-4 from BD Biosciences.
Generation of fusion proteins. The cDNA sequence encoding the human Fc-fragment of IgG1 was cloned into a pCR3-derived human Flag-CD95L (CD95L, amino acids 95-282) protein expression vector provided by Harald Wajant (Würzburg, Germany). The Fc-Flag-CD95L pCR3 construct was modified by inserting a Strep-tag coding sequence, resulting in a Strep-Fc-Flag-CD95L pCR3 construct. Fusion proteins were generated as described. 37 The leucine zipper LZ-CD95L was prepared as previously described. 38 Proliferation assays: [ 3 H]-thymidine (tdR) and BrdU incorporation, MTS assay and CFSE distribution assay. 96-well flat-bottom TC plates were coated for 3 h at 371C with 50 ml of OKT3, with or without anti-CD28. Anti-CD95 mAb (7C11 or anti-APO-1), CD95L fusion proteins or human IgGFc control protein were included in the coating solution as indicated. For the bromodeoxyuridine (BrdU) assay, we used the BrdU Labeling and Detection Kit III (Roche, Grenzach-Wyhlen, Germany). Stimulated cells (d2) were incubated with BrdU labeling reagent for 16 h. The incorporation of BrdU was determined by an ELISA using a POD-labeled anti-BrdU antibody. [ 3 H]-TdR incorporation was measured as described before 37 . Alternatively, proliferation was analyzed using a colorimetric MTS/PMS assay (CellTiter96 AQueous Non-Radioactive Cell Proliferation Assay, Promega, Mannheim, Germany) according to the manufacturer's instructions. The optical densities of individual culture wells were read in a microplate reader at 490 nm. For the CFSE dilution assay, purified CD4 þ T cells were labeled with 5-(6-)carboxyfluorescein diacetate succinimidyl ester (CFSE), and analyzed by flow cytometry. 37 
